

AKUMS
DRUGS & PHARMACEUTICALS LTD.



Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I,
(Adjoining CBSE Office) Delhi - 110083 (INDIA).

www.akums.in

akumsho@akums.net

+91-11-69041000

CIN: L24239DL2004PLC125888

+91-11-27023256

Ref: Akums/Exchange/2025-26/28

July 18, 2025

To,
The Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

To,
The Listing Department
BSE Limited
25th Floor, New Trading Ring,
Rotunda Building, Phiroze Jeejeebhoy
Towers, Dalal Street, Mumbai - 400 001

Symbol: AKUMS

Scrip Code: 544222

**Sub: Proceedings of 21st Annual General Meeting under Regulation 30 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations 2015**

Respected Sir/Mam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed herewith the proceedings of the 21st Annual General Meeting of the Company held through Video Conference (VC)/ Other Audio-Visual Means (OAVM) on 18th July, 2025 at 11:00 AM (IST) and concluded at 11:57 AM (IST).

This is for your kind information and record.

Thanking You

Yours Faithfully
For **Akums Drugs and Pharmaceuticals Limited**

Dharamvir Malik
Company Secretary & Compliance Officer

Encl.: As above

Registered Office

304, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA).

+91-11-47511000

+91-11-27023256

Summary of Proceedings of the 21st Annual General Meeting (“AGM”) of the Members of Akums Drugs and Pharmaceuticals Limited (“the Company”) held on Friday, July 18, 2025.

The 21st AGM of the Members of the Akums Drugs and Pharmaceuticals Limited (“the Company”) was held on Friday, July 18, 2025 at 11.00 am (IST) through two-way Video Conferencing (‘VC’)/ Other Audio Visual Means (‘OAVM’). The meeting was conducted in accordance with relevant Circulars issued by the Ministry of Corporate Affairs (‘MCA’) and the Securities Exchange Board of India (‘SEBI’) in this regard.

Mr. Dharamvir Malik, Company Secretary & Compliance Officer welcomed the members to the meeting and briefed them on certain important points relating to the participation at the meeting and voting at this AGM.

The Company Secretary informed that the Company has received letters and Board Resolutions from certain corporate & trusts appointing their authorized representatives to join the AGM. These shareholders holds a total 7,57,70,465 equity shares, representing 48.141% of the Company’s total paid up equity share capital. Further he informed that the Statutory Registers as required under Companies Act, 2013 were available for inspection in electronic mode at the NSDL portal.

Mr. Sandeep Jain, Managing Director of the Company, chaired the meeting. He welcomed the members to the meeting. Upon confirming the requisite quorum being present, total 111 shareholders attended the meeting, the Chairman called the meeting to order. He welcomed the Directors and requested those, who joined through VC, to introduce themselves to the members. He also introduced Chief Financial Officer and Company Secretary present in the AGM. The respective Chairpersons of the Audit Committee, Stakeholder Relationship Committee, Nomination and Remuneration Committee, Corporate Social Responsibility Committee were present at the AGM. The representatives of the Company’s Statutory Auditors and Secretarial Auditors were also present at the meeting through VC.

The Chairman addressed the members embarking the journey of Akums from its inception and marking a significant milestone as this was the first AGM held after Company’s successful IPO and listing on both the stock exchanges, NSE and BSE. He highlighted the Company’s evolution since 2004, when the first manufacturing facility was established in Haridwar, and its continued commitment to producing high-quality medicines at affordable prices. The Company has now grown to 14 state-of-art manufacturing facility (11 formulations and 3 API facilities), with two additional formulations units in the pipeline, and three R&D facilities.

Thereafter, the Chairman highlighted the performance of this financial year where he stated the Company demonstrated commendable resilience in its performance.

He emphasized the Company’s strong performance during the financial year and highlighted key developments.

- i) Execution of a landmark CDMO contract worth approximately EUR 200 million with a global pharmaceutical’s leader for the European market.
- ii) Expansion of manufacturing capacity through new facilities at Haridwar (Injectables), Kotdwar (Panem Anti-infectives), and Baddi (Muti-dosage formats).

Registered Office

304, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA).

+91-11-47511000

+91-11-27023256

- iii) Expenditure of Rs 130 crores in R&D, resulting in 31 DCGI approvals and 117 FSSAI approvals.
- iv) Strengthening of strategic-in-licensing partnership with global players like Triple Hair Inc, (Canada) and Caregen (South Korea).
- v) Continued commitment to sustainability and ESG initiatives.

In his closing remarks, the Chairman noted that Financial year 2025 was not just a year of resilience but also year of learning and transformation, and strategic growth. He expressed gratitude to the shareholders, employees, clients and partners and valuable guidance of Board members.

The Company Secretary informed that the Notice of AGM along with Integrated Annual Report had already been circulated to the members in the prescribed manner and also hosted on the website of the Company, BSE Limited and National Stock Exchange of India Limited and National Securities Depositories Limited ("NSDL") were taken as read.

The Company Secretary informed the members that the Company had provided remote e-voting facility on the resolutions proposed in the Notice of the 21st AGM from 13th July 2025 (9.00 AM IST) to 17th July, 2025 (5.00 PM IST). He further informed that those members, who have not yet casted their vote, may cast their vote during the meeting, and the e-voting facility will also remain open for 15 minutes after the conclusion of the meeting.

The Company Secretary read out the following agenda items No1to 5 of the Notice of 21st AGM.

- 1) To adopt Standalone & Consolidated financial statements for the Financial year 2024-25 and the Reports of Auditors' and Directors' thereon.
- 2) To appoint Shri Sanjeev Jain, as a Director, who retire by rotation & being eligible offer himself for re-appointment.
- 3) Appointment of Secretarial Auditors for five financial years from FY 2025-26 to FY 2029-30.
- 4) Ratification of the remuneration payable to the Cost Auditors of the Company for the Financial Year 2025-26.
- 5) Appointment of Mr. Anil Amin as an Independent Director of the Company.

The Company Secretary invited speaker shareholders who had pre-registered themselves with the Company to express their views and offer their valuable comments.

The Chairman responded to the questions of the shareholders.

Thereafter, the Chairman authorised Company Secretary to conclude the AGM.

The Company Secretary thanked Chairman sir and all the shareholders of the Company who have participated in the AGM and concluded the meeting with the permission of Chairman at 11.57 am (IST).

Thanking you,

For **Akums Drugs and Pharmaceuticals Limited**

Dharamvir Malik
Company Secretary & Compliance Officer